{
    "clinical_study": {
        "@rank": "104118", 
        "arm_group": [
            {
                "arm_group_label": "Group 1", 
                "description": "Patients ex. Arm 1 SP848-AK-1101 trial"
            }, 
            {
                "arm_group_label": "Group 2", 
                "description": "Patients ex. Arm 2 SP848-AK-1101 trial"
            }, 
            {
                "arm_group_label": "Group 3", 
                "description": "Patients ex. Arm 3 SP848-AK-1101 trial"
            }, 
            {
                "arm_group_label": "Group 4", 
                "description": "Patients ex. Arm 4 SP848-AK-1101 trial"
            }, 
            {
                "arm_group_label": "Group 5", 
                "description": "Patients ex. Arm 5 SP848-AK-1101 trial"
            }
        ], 
        "brief_summary": {
            "textblock": "Determine the recurrence rate of actinic keratosis (AK) lesions in patients with complete\n      clinical clearance at the end of the previous trial SP848-AK-1101 at 6 and 12 months of\n      follow-up."
        }, 
        "brief_title": "Observational Trial Assessing Long-term Local Tolerability and Efficacy of Resiquimod Gel in Patients Treated for Actinic Keratosis.", 
        "completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Actinic Keratosis", 
        "condition_browse": {
            "mesh_term": [
                "Keratosis", 
                "Keratosis, Actinic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Signed informed consent.\n\n          -  Participation in the previous clinical trial SP848-AK-1101.\n\n          -  Patient with complete clinical clearance (i.e. no previously existing AK-lesion\n             present) at the end of the trial SP848-AK-1101 or Non-Responder who withdrew from the\n             trial prematurely.\n\n        Exclusion Criteria:\n\n          -  Evidence of unstable or uncontrolled clinically significant medical conditions as\n             determined by the investigator (e.g., cardiovascular, immunological, hematologic,\n             hepatic, neurologic, renal, endocrine, collagen-vascular, infectious,\n             gastrointestinal abnormalities or diseases).\n\n          -  Evidence of systemic cancer.\n\n          -  Dermatological disease or condition in the former treatment or surrounding area that\n             might impair trial assessments (e.g., rosacea, atopic dermatitis, eczema) as assessed\n             by the investigator."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patient with complete clinical clearance (i.e. no previously existing AK-lesion present)\n        at the end of the trial SP848-AK-1101 or Non- Responder who withdrew from the trial\n        prematurely."
            }
        }, 
        "enrollment": {
            "#text": "16", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 6, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01806961", 
            "org_study_id": "SP848-AKEx-1209"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "October 24, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Berlin", 
                        "country": "Germany"
                    }, 
                    "name": "Hauttumorcentrum Charit\u00e9 (HTCC)"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bonn", 
                        "country": "Germany"
                    }, 
                    "name": "Medizinisches Zentrum Bonn - Friedensplatz"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "D\u00fcsseldorf", 
                        "country": "Germany"
                    }, 
                    "name": "Hautzentrum"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Minden", 
                        "country": "Germany"
                    }, 
                    "name": "Johannes Wesling Klinikum Minden"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Recklinghausen", 
                        "country": "Germany"
                    }, 
                    "name": "KLINIKUM VEST GmbH Knappschaftskrankenhaus"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Basel", 
                        "country": "Switzerland"
                    }, 
                    "name": "Universit\u00e4tsspital Basel"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bern", 
                        "country": "Switzerland"
                    }, 
                    "name": "Inselspital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St. Gallen", 
                        "country": "Switzerland"
                    }, 
                    "name": "Kantonsspital St.Gallen"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Zurich", 
                        "country": "Switzerland"
                    }, 
                    "name": "Universitaetsspital Zurich"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "Germany", 
                "Switzerland"
            ]
        }, 
        "number_of_groups": "5", 
        "official_title": "Observational (Non-interventional), Follow-up Trial Assessing Long-term Local Tolerability and Efficacy (Recurrence Rate) of Resiquimod Gel in Patients Treated for Actinic Keratosis.", 
        "overall_official": {
            "affiliation": "University Clinic of Dermatology, Zurich", 
            "last_name": "Lars E French, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Terminated", 
        "oversight_info": {
            "authority": [
                "Switzerland: Ethikkommission", 
                "Switzerland: Swissmedic", 
                "Germany: Ethics Commission", 
                "Germany: Federal Institute for Drugs and Medical Devices"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Number of patients with persistent complete clearance at 6 and 12 months follow-up. Recurrence rate is to be determined at the same treatment area where the investigational medicinal products were administered in the previous trial.", 
            "measure": "Determine the recurrence rate of AK-lesions", 
            "safety_issue": "No", 
            "time_frame": "at 6 and 12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01806961"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Occurrence of new AK-lesions within the former treatment area", 
                "safety_issue": "No", 
                "time_frame": "at 6 and 12 months"
            }, 
            {
                "measure": "Number of newly occurred dermal adverse and serious adverse events on the previous treatment area", 
                "safety_issue": "Yes", 
                "time_frame": "at 6 and 12 months"
            }
        ], 
        "source": "Spirig Pharma Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Spirig Pharma Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "October 2013"
    }
}